Letter to the editor: Episodic‐precipitant–induced hepatic encephalopathy treatment: Look at new and old precipitants!
Lorenzo Ridola, Silvia Nardelli, Stefania Gioia, Jessica Faccioli, Oliviero Riggio – 23 December 2021
Reply
Vincent L. Chen, Nathan S. Ramrakhiani, Mindie H. Nguyen – 23 December 2021
Reply
Arpan Jain, Barjesh Chander Sharma – 23 December 2021
Letter to the editor: Importance of universal screening for chronic hepatitis B infection in adults in the United States
Chari Cohen, Kate Moraras, Michalea Jackson, Maureen Kamischke, Robert G. Gish, Carol L. Brosgart, Mehlika Toy, David Hutton, Timothy M. Block, Su Wang, Samuel So – 23 December 2021
Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease
Nobuyoshi Kawamura, Kento Imajo, Kyle J. Kalutkiewicz, Koki Nagai, Michihiro Iwaki, Takashi Kobayashi, Asako Nogami, Yasushi Honda, Takaomi Kessoku, Yuji Ogawa, Takuma Higurashi, Kunihiro Hosono, Hirokazu Takahashi, Masato Yoneda, Satoru Saito, Shinichi Aishima, Hidenori Toyoda, Hideki Hayashi, Yoshio Sumida, Richard L. Ehman, Atsushi Nakajima – 23 December 2021
Immunological Aspects of AXL/GAS‐6 in the Context of Human Liver Regeneration
Gregor Ortmayr, Laura Brunnthaler, David Pereyra, Heidemarie Huber, Jonas Santol, Benedikt Rumpf, Sina Najarnia, Rory Smoot, Daphni Ammon, Thomas Sorz, Fabian Fritsch, Michael Schodl, Astrid Voill‐Glaninger, Barbara Weitmayr, Manuela Födinger, Martin Klimpfinger, Thomas Gruenberger, Alice Assinger, Wolfgang Mikulits, Patrick Starlinger – 23 December 2021 – AXL and its corresponding ligand growth arrest–specific 6 (GAS‐6) are critically involved in hepatic immunomodulation and regenerative processes.
Advances in Predictive Modeling Using Machine Learning in the Field of Hepatology
Camille A. Kezer, Vijay H. Shah, Douglas A. Simonetto – 22 December 2021
Progressive Scale‐up of HBV AND HCV Testing for Hepatitis Elimination in Vietnam
Tran Nguyen, Trang Pham, Loc Phan, Gary Mize, Amy Trang, Diem Dao, Anh Le, Robert Gish, William M. Lee, Dung Do, Hong K. Tang, Hai T. Phan, Binh T. Nguyen, Doan Y Dao – 22 December 2021
Angiotensin Converting Enzyme‐2 Therapy Improves Liver Fibrosis and Glycemic Control in Diabetic Mice With Fatty Liver
Indu G. Rajapaksha, Lakmie S. Gunarathne, Khashayar Asadi, Ross Laybutt, Sof Andrikopoulous, Ian E. Alexander, Mathew J. Watt, Peter W. Angus, Chandana B. Herath – 22 December 2021 – Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease and is frequently associated with type 2 diabetes. However, there is no specific medical therapy to treat this condition. Angiotensin‐converting enzyme 2 (ACE2) of the protective renin angiotensin system generates the antifibrotic peptide angiotensin‐(1‐7) from profibrotic angiotensin II peptide.
A strategy of vascular‐targeted therapy for liver fibrosis
Yuan Lin, Meng‐Qi Dong, Zhi‐Min Liu, Meng Xu, Zhi‐Hao Huang, Hong‐Juan Liu, Yi Gao, Wei‐Jie Zhou – 22 December 2021